Holen Sie sich die Stockscreener-App
1.73
20.64%
-0.45
iBio Inc Aktie (IBIO) Neueste Nachrichten
Panic Selling: Is iBio Inc impacted by rising ratesWeekly Stock Recap & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Insider Buying: Felipe Duran Acquires Shares of iBio Inc (IBIO) - GuruFocus
INB.bio Launches Rebuilt Ai-Powered Affiliate Crm Platform - marketscreener.com
Martin Brenner Purchases 12,336 Shares of iBio (NASDAQ:IBIO) Stock - MarketBeat
iBio (NASDAQ:IBIO) CFO Felipe Duran Acquires 24,835 Shares - MarketBeat
iBio CFO Duran acquired $50k in shares on March 19 - Investing.com
iBio director Brenner buys $24918 in company stock By Investing.com - Investing.com Australia
iBio director Brenner buys $24918 in company stock - Investing.com
IBIO | iBio, Inc. Common Stock Insider Trading - Quiver Quantitative
iBio CFO Duran acquired $50k in shares on March 19 By Investing.com - Investing.com South Africa
CFO adds 24,835 iBio (NYSE: IBIO) shares in open-market purchase - Stock Titan
iBio (IBIO) director makes open-market purchase of 12,336 shares - Stock Titan
Aug Action: Is iBio Inc a speculative investmentTrade Analysis Report & Weekly High Return Forecasts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Ibio (IBIO) Receives a Buy from LifeSci Capital - The Globe and Mail
History Review: Can iBio Inc stock double in the next yearTake Profit & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
iBio (NASDAQ:IBIO) Cut to Sell at Wall Street Zen - MarketBeat
Aug Movers: Is iBio Inc impacted by rising rates2026 Earnings Surprises & Weekly Top Stock Performers List - baoquankhu1.vn
iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 - MarketBeat
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
IBIO: Analyst Keay Nakae Reaffirms 'Buy' Rating with $5.00 Price Target | IBIO Stock News - GuruFocus
Aug Opening: How do insiders feel about iBio IncQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion By Investing.com - Investing.com South Africa
Jones Trading reiterates iBio stock rating on pulmonary hypertension expansion - Investing.com India
VIX Spike: Is IBIO in a long term uptrend2026 PreEarnings & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
iBio (NASDAQ:IBIO) Given Buy Rating at Chardan Capital - MarketBeat
iBio (IBIO) to Discuss Pipeline Expansion in Upcoming Conference Call - GuruFocus
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) - The Manila Times
Stop Loss: How sensitive is iBio Inc to inflationWeekly Gains Report & Real-Time Chart Pattern Alerts - baoquankhu1.vn
iBio reports fat reduction in primate obesity study By Investing.com - Investing.com Nigeria
Ibio SEC Filings - Stock Titan
iBio, Inc. (NASDAQ:IBIO) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Highs Report: Is iBio Inc a turnaround storyRate Cut & Reliable Price Action Trade Plans - baoquankhu1.vn
IBIO: Advancing novel antibody therapies for obesity and cardiometabolic disease with strong clinical momentum - TradingView
Jones Trading reiterates iBio stock rating on obesity drug data - Investing.com
Jones Trading reiterates iBio stock rating on obesity drug data By Investing.com - Investing.com UK
iBio Reports Promising Preclinical Results for IBIO-610 Activin E Antibody in Fat-Selective Weight Loss for Obesity and Cardiometabolic Diseases 1 - Minichart
IBIO: Innovative antibody pipeline aims for fat-specific weight loss and muscle preservation in obesity - TradingView
iBio reports fat reduction in primate obesity study - Investing.com
iBio Highlights IBIO-610 Obesity and Cardiometabolic Potential - TipRanks
iBio (IBIO) Reports Promising Preclinical Results for Obesity Tr - GuruFocus
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss - Bitget
Primate obesity study backs iBio fat-loss antibody, twice-yearly dosing potential - Stock Titan
[EFFECT] iBio, Inc. SEC Filing - Stock Titan
Leerink Partners Maintains IBio Inc(IBIO.US) With Buy Rating, Raises Target Price to $5 - 富途牛牛
Cash per share of iBio, Inc. – MUN:0JV0 - TradingView
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ:IBIO) Upgraded by JonesTrading to Strong-Buy Rating - MarketBeat
Jones Trading Initiates Coverage of iBio (IBIO) with Buy Recommendation - Nasdaq
JonesTrading Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
iBio (IBIO) Receives New 'Buy' Rating from Jones Trading | IBIO Stock News - GuruFocus
iBio (NYSE:IBIO) Now Covered by Analysts at JonesTrading - MarketBeat
Jones Trading initiates iBio stock with buy rating on obesity platform - Investing.com Australia
Jones Trading initiates iBio stock with buy rating on obesity platform By Investing.com - Investing.com South Africa
0.99%
3.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):